Online Media Kit


March 16, 2022 | Times LIVE (South Africa)

More HIV prevention options for SA women as vaginal ring approved

The South African Health Products Regulatory Authority (SAHPRA) okayed the use of the monthly dapivirine vaginal ring by adult women. More »


February 26, 2022 | The East African (Kenya)

Young women prefer vaginal ring to daily oral pill for HIV prevention

Given a choice between two HIV prevention products, most adolescent girls and young women who had used both products while participating in the REACH study chose the monthly dapivirine ring. More »


January 26, 2021 | World Health Organization

WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection

WHO recommended that the dapivirine vaginal ring, a female-initiated option to reduce the risk of HIV infection, may be offered as an additional prevention choice for women at substantial HIV risk as... More »

Media Highlights

November 30, 2020 | Healio

Dapivirine vaginal ring receives WHO prequalification for HIV prevention

The dapivirine vaginal ring has been prequalified by WHO, bringing the HIV preventive closer to public introduction and approval by individual countries. More »

November 20, 2020 | Manica Post (Zimbabwe)

Strides in HIV response

The dapivirine ring could have a meaningful public health impact as the first long-acting HIV prevention tool designed specifically for women. More »

November 17, 2020 | Women's Voice (Zimbabwe)

Dapivirine Ring: A Game-Changer For Women In Zimbabwe

The dapivirine vaginal ring is a user-controlled, monthly HIV prevention method for women. More »

October 08, 2020 | YonecoFM (Malawi)

Dapivirine vaginal ring to be ready for use in 2021

According to Bamusi, the method is currently being assessed by international health bodies before it is approved for use among women in the country. More »

October 07, 2020 | Malawi24

International body approves vaginal ring

The dapivirine ring for HIV prevention received a positive opinion from the European Medicines Agency. More »